PRESS RELEASES 20202020March 26, 2020 - VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal StudyMarch 19, 2020 - VBL Therapeutics Announces Year Ended December 31, 2019 Financial Results and Provides Corporate UpdateMarch 3, 2020 - VBL Therapeutics to Report Fourth Quarter 2019 Financial Results on March 19February 20, 2020 - VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal CancerJanuary 8, 2020 - VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study
